TIDMBTG
RNS Number : 9604H
BTG PLC
16 June 2017
ACCESS PTS Study Demonstrates Efficacy of EKOS(R) Therapy for
Post-Thrombotic Syndrome
Bothell, WA, 16 June 2017: BTG plc (LSE: BTG), the global
specialist healthcare company, today highlights the results of the
ACCESS PTS trial, presented at the Society for Vascular Medicine
28(th) Annual Scientific Sessions in New Orleans, June 14 to 17.
The study found chronic deep vein thrombosis (DVT) patients with
post-thrombotic syndrome (PTS) can be treated safely and
effectively with EKOS(R) therapy. The ACCESS PTS protocol using
EKOS(R) therapy is now the only treatment regimen proven to
significantly reduce the signs and symptoms of PTS and show a
significant improvement in quality of life.
The ACCESS PTS study is a multicenter prospective single-arm
study of 73 patients with iliofemoral DVT, meeting eligibility
including a Villalta Score of 8 or greater (Villalta Score measures
the signs and symptoms of PTS), and who had failed three months of
conservative therapy. Patients were treated with anticoagulation
drugs followed by EKOS(R) therapy with balloon dilatation.
The study met its primary efficacy endpoint and showed a
significant improvement of Villalta Scores of 34% at 30 days across
77 limbs treated among the 73 patients with a p-value of
<0.0001. On average, patients treated in the study experienced a
symptom reduction from severe down to borderline mild. The study
also showed a 21% improvement in patients' quality of life.(1)
There was one bleeding incident and one PE - meeting the study's
safety endpoint.
"ACCESS PTS demonstrates that EKOS(R) therapy with balloon
dilatation is effective and safe in reducing the signs and symptoms
of post-thrombotic syndrome for patients suffering from chronic
deep vein thrombosis, while improving their quality of life," said
lead investigator Dr. Mark Garcia of Vascular & Interventional
Associates of Delaware in Wilmington, Delaware. "EKOS(R) therapy is
a useful and important option for physicians treating debilitating
chronic DVT and PTS."
In addition to Dr. Garcia, the study's authors include Dr. Keith
Sterling of Inova Alexandria Hospital; Dr. Michael Jaff of
Newton-Wellesley Hospital; Dr. Kenneth Ouriel of Syntactx; Dr.
Susan Kahn of Jewish General Hospital; and Dr. Anthony Comerota of
Jobst Vascular Institute.
"With the ACCESS PTS study, BTG is once again demonstrating our
commitment to advancing the treatment of VTE patients. Chronic DVT
can be both debilitating and life threatening. Until now, most
chronic DVT and PTS sufferers had no other treatment options," said
EKOS(R) Vice President and General Manager Matt Stupfel. "The
ACCESS PTS data proves that EKOS(R) therapy is a safe and effective
option for treating chronic DVT. EKOS(R) is setting the standard
for interventional chronic-DVT treatment, getting patients back on
their feet and on with their lives."
About Chronic Deep Vein Thrombosis
Deep Vein Thrombosis (DVT) is a debilitating and potentially
life threatening condition. It occurs when a blood clot forms in
one of the deep veins in your body, limiting blood flow. It usually
occurs in your leg or pelvis, but it can also occur in your arm or
chest. If the clot isn't dissolved within a few weeks, it can
become a Chronic Deep Vein Thrombosis. When this happens, the blood
clot interferes with blood flow and can permanently damage the
valves in your veins(2) creating a condition call Post-Thrombotic
Syndrome (PTS). About 50% of patients with chronic DVT in the upper
leg area may develop PTS which can cause disability and negatively
impact the quality of life.(2,3) Prior to ACCESS PTS, there was no
proven treatment option for PTS.
About the EkoSonic(R) Endovascular System
The EKOS(R) system uses ultrasonic waves in combination with
clot-dissolving thrombolytic drugs to effectively dissolve clots
and restore healthy blood flow.
In clinical studies EKOS(R) therapy has been shown to speed
time-to-clot dissolution, increase clot removal and enhance
clinical improvement compared to either standard catheter-directed
drug therapy or thrombectomy. EKOS(R) therapy requires
significantly shorter treatment times and less thrombolytic
compared to standard catheter-directed drug therapy, lowering the
risk of bleeding and other complications.
(1) As measured by VEINES-QOL
(2) Ashrani AA, Heit JA. J Thromb Thrombolysis.
2009;28::465-476.
(3) Kahn, S et al. Arch Intern Med 2004; 164:17-26.
For further information contact:
BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
US Inquiries: Greentarget Communications
Chris Gale, Vice President
+1-646-695-2883; Mobile: +1-203-570-4681
UK Inquiries: FTI Consulting
Ben Atwell, Senior Managing Director
+44 (0)20 3727 1000
Simon Conway, Senior Managing Director
+44 (0)20 3727 1000
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFXLFFDQFXBBK
(END) Dow Jones Newswires
June 16, 2017 02:00 ET (06:00 GMT)
Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024
Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024